Email Updates

You are here


Media Coverage

  • Zimbabwe's national drug procurer NatPharm has assured Zimbabweans on second-line regimen antiretroviral (ARV) treatment that the currently low stocks of medication will soon be replenished.

    September 3, 2020
  • American scientists have developed an injectable drug that blocks HIV from entering cells. They say the new drug potentially offers long-lasting protection with fewer side effects and could eventually replace drug ‘cocktail’ therapies.

    September 3, 2020
    Health-E News
  • According to the director of programs and advocacy at international community of women living with HIV Eastern Africa (ICWEA), Dorothy Namutamba, there has been meagre support from government towards access and utilization of quality and comprehensive HIV/AIDS care services across the country.

    September 3, 2020
    New Vision
  • The COVID-19 pandemic tends to conceal other important health issues. One of these is the global target for reducing HIV infections and increasing access to treatment. Progress is well under way. In 2019, 67 percent of those living with HIV were receiving antiretroviral therapy (ART), and 85 percent of pregnant women with HIV were receiving medication to prevent transmission to their babies.

    September 3, 2020
    The Conversation
  • Loreen Willenberg had always been an “elite controller” – a person who maintains an undetectable viral load without having to take HIV drugs – but now her doctors can find no trace of the virus anywhere in her body.

    September 3, 2020
  • This summer marked an important milestone for preventing HIV in women and a beautiful moment for me. On July 24, the Dapivirine Vaginal Ring, the first long acting HIV prevention product for women and a major subject of my research at the Women’s Global Health Imperative, moved one step closer to real-world access. After years of uncertainty and delays, the European Medicines Agency provided a positive scientific opinion about the ring. This decision places the ring on the path toward regulatory approval, so that globally, women who need protection from HIV have more options.

    September 2, 2020
  • Scientists at the University of Utah have developed an injectable HIV prevention and treatment drug that will soon be in human trials after showing good results in macaque monkeys.

    September 1, 2020
    HIV Plus Mag
  • During the initial wave of COVID-19 cases in March, many health care centers put HIV prevention and community outreach initiatives on the back burner. As a result, both prevention and treatment options became less available, which directly impacted usage. A U.S. survey of 394 pre-exposure prophylaxis (PrEP) users from April noted that the percentage of respondents who took PrEP daily fell from 95.3 percent to 61.6 percent after the COVID-19 pandemic began. (The other 4.7 percent were taking event-based PrEP.

    August 31, 2020
    The BodyPro
  • Fifty years ago, few scientists believed a drug could fight viruses with low side effects. Then Gertrude Elion showed the doubters "what I could do on my own."

    August 31, 2020
    National Geographic
  • Back in March, Quadeer Jones, a 23-year-old actor in Los Angeles, decided to get pre-exposure prophylaxis, or PrEP, to protect himself from HIV when having sex. He made an appointment at the Los Angeles LGBT Center to get PrEP medication, the antiretroviral Truvada, traveling more than 30 miles. Once he arrived at the center, the process was relatively easy. “I had to schedule an appointment for rapid HIV testing,” he says. “They said I was negative. I got my prescription and meds and I was out the door in about an hour.”

    July 7, 2020
    Capital & Main

Published Research